§ Federal grant opportunity · RFA-CA-27-005
Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
National Institutes of Health is accepting applications for Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required). The deadline is January 11, 2027 and the published award range is $700K.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- January 11, 2027
- Award range
- $700K
- Eligibility
- small businesses, city or township governments, for profit organizations other than small businesses, private institutions of higher education, state governments, other native american tribal organizations, other, nonprofits non higher education without 501c3, special district governments, public and state institutions of higher education, nonprofits non higher education with 501c3, county governments, federally recognized native american tribal governments, independent school districts, public and indian housing authorities
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- RFA-CA-27-005
Program overview
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms. To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through investigational new drugs (IND) studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: (1) novel agents or (2) agents or combinations approved for other indications and repurposed for treatment of GBM following appropriate preclinical studies. The scope of the NOFO, from late pre-clinical through early (Phase 0/1) clinical studies, uniquely spans a gap in the GBM drug development process.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before January 11, 2027, allowing time for registration and validation.
Related grant opportunities
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.